FindTrial
Sign In

maplirpacept (PF-07901801)

DRUG4 trials

Sponsors

Pfizer

Conditions

Acute Myeloid LeukemiaDiffuse Large B-Cell LymphomaEpithelial Ovarian CancerFallopian Tube CancerLymphomaMultiple MyelomaOvarian CancerOvarian Carcinoma

Phase 1

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
TerminatedNCT03530683
PfizerAcute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma, Lymphoma +1
Start: 2018-05-14End: 2024-07-18Updated: 2024-09-03
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
TerminatedNCT05261490
PfizerEpithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer +3
Start: 2022-08-01End: 2024-02-15Updated: 2024-11-19
A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
CompletedNCT05567887
PfizerLymphoma, Multiple Myeloma
Start: 2022-11-02End: 2024-10-02Updated: 2024-11-06
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
TerminatedNCT05896163
PfizerDiffuse Large B-Cell Lymphoma
Start: 2023-08-30End: 2026-04-09Updated: 2026-05-06

Related Papers

A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results.
Journal of Clinical Oncology2024-06-012 citations
A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Glofitamab in People with Relapsed or Refractory Diffuse Large B Cell Lymphoma
Blood2023-11-022 citations
A Multicenter, Open-Label, Phase 1b/2 Study to Evaluate the Effects of Maplirpacept in Combination with Tafasitamab and Lenalidomide in People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Blood2023-11-021 citations
TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.
Journal of Clinical Oncology2022-06-018 citations
PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
HemaSphere2022-06-012 citations
TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL).
Journal of Clinical Oncology2022-06-011 citations
CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
Blood2021-11-0526 citations
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
Blood2020-11-0415 citations
Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.
Journal of Clinical Oncology2020-05-208 citations